CG Oncology (CGON) Debt Ratio (2025 - 2026)
CG Oncology (CGON) posted Debt Ratio of 0.0 for Q1 2026, down 30.27% on a QoQ basis from 0.0 in Q4 2025.
CG Oncology (CGON) Debt Ratio (2025 - 2026) Analysis & Trends
CG Oncology's Debt Ratio history runs 2 years deep, the most recent figure standing at 0.0 for Q1 2026.
- Quarterly Debt Ratio changed N/A year-over-year to 0.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.0 (changed N/A YoY) and the FY2025 annual result came in at 0.0, changed N/A from the prior year.
- Debt Ratio was 0.0 for Q1 2026 at CG Oncology, down from 0.0 in the prior quarter.
- Across five years, Debt Ratio topped out at 0.0 in Q3 2025 and bottomed at 0.0 in Q1 2026.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt Ratio (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 1.41 |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 0.11 |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 0.05 |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | CG Oncology | 5.86 Bn | 5.86 Bn | -1.88 Mn | 0.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.00 |
| Dec 31, 2025 | 0.00 |
| Sep 30, 2025 | 0.00 |